SOP Therapieassoziierte Anämie

Die Anämie ist ein häufig vorkommendes Krankheitsbild bei Patienten mit Tumorerkrankungen, insbesondere unter tumorspezifischer Therapie. Mit der Differenzialdiagnostik und gezielten therapeutischen Optionen sollte der behandelnde Mediziner vertraut sein. Zum Thema der tumor- und therapieassoziierten Anämie soll der Artikel einen Überblick und Handlungsempfehlungen geben.

Schlüsselwörter

Hämoglobin - Erythropoese - Krebstherapie - Erythropoetin - Tumortherapie

Publikationsverlauf

Artikel online veröffentlicht:
12. Juni 2024

• Literatur

• 1 Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004; 116(Suppl. 7A): 11S-26S
• 2 Ludwig H, Van Belle S, Barrett-Lee P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306
• 3 Harrison LB, Shasha D, White C. et al. Radiotherapy-associated anemia: the scope of the problem. Oncologist 2000; 5 (Suppl. 2) 1-7
• 4 Onkopedia. Eisenmangel und Eisenmangelanämie. 2022 Zugriff am 05. Februar 2024 unter: https://www.onkopedia.com/de/onkopedia/guidelines/eisenmangel-und-eisenmangelanaemie/@@guideline/html/index.html
• 5 Hahn J-M. Checkliste Innere Medizin. 9. Aufl.. Stuttgart: Thieme; 2023
• 6 Medizinische Laboratorien Düsseldorf. Erythropoetin (EPO). Zugriff am 05. Februar 2024 unter: https://www.labor-duesseldorf.de/examination/view/erythropoetin-epo
• 7 Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023
• 8 Miller CB, Jones RJ, Piantadosi S. et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689-1692
• 9 Fleming RE, Bacon BR. Orchestration of iron homeostasis. N Engl J Med 2005; 352: 1741-1744
• 10 Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117: 4425-4433
• 11 Kautz L, Jung G, Nemeth E. et al. The erythroid factor erythroferrone and its role in iron homeostasis. Blood 2013; 122: 4
• 12 Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta 2013; 1836: 245-254
• 13 Ludwig H, Müldür E, Endler G. et al. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013; 24: 1886-1892
• 14 Henry DH, Dahl NV, Auerbach M. et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242
• 15 Auerbach M, Ballard H, Trout JR. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307
• 16 Macciò A, Madeddu C, Gramignano G. et al. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist 2010; 15: 894-902
• 17 Steensma DP, Sloan JA, Dakhil SR. et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011; 29: 97-105
• 18 Steinmetz T, Tschechne B, Harlin O. et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013; 24: 475-482
• 19 Tonia T, Mettler A, Robert N. et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; (12) CD003407
• 20 Cella D, Eton DT, Lai JS. et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002; 24: 547-561
• 21 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen. AWMF-Registernummer: 032/054OL. 2020. Zugriff am 11. März 2024 unter: https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie/
• 22 Moebus V, Jackisch C, Schneeweiss A. AGO Breast Study Group. et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013; 105: 1018-1026
• 23 Nitz U, Gluz O, Zuna I. West German Study Group. et al. Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann Oncol 2014; 25: 75-80
• 24 McFarland JG. Perioperative blood transfusions: indications and options. Chest 1999; 115 (Suppl. 5) 113S-121S
• 25 Aapro M, Beguin Y, Bokemeyer C. et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29 (Suppl. 4) iv271
• 26 Rizzo JD, Brouwers M, Hurley P. et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28: 4996-5010
• 27 Hicks LK, Bering H, Carson KR. et al. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Blood 2013; 122: 3879-3883
• 28 Aapro M, Beguin Y, Bokemeyer C. et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29: iv96-iv110
• 29 Onkopedia-Leitlinie. Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen. 2018.
• 30 Link H, Schmitz S. Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany. Onkologie 2013; 36: 266-272